NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain

Bioorganic & Medicinal Chemistry Letters
1999.0

Abstract

Using an NMR-based screen, a series of novel phosphotyrosine mimetics were discovered that bind to the SH2 domain of Lck. These compounds may serve as useful leads for the design of nonpeptide inhibitors of SH2 domains with improved bioavailability and metabolic stability compared to the natural ligands that contain phosphotyrosine.

Knowledge Graph

Similar Paper

NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain
Bioorganic & Medicinal Chemistry Letters 1999.0
Conformationally Constrained Phosphotyrosyl Mimetics Designed as Monomeric src Homology 2 Domain Inhibitors
Journal of Medicinal Chemistry 1995.0
Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein
Bioorganic & Medicinal Chemistry Letters 2002.0
The structure–activity relationship of the series of non-peptide small antagonists for p56lck SH2 domain
Bioorganic & Medicinal Chemistry 2007.0
Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers
Bioorganic & Medicinal Chemistry Letters 2000.0
Actinomycin D, C2 and VII, inhibitors of Grb2-SHc interaction produced by Streptomyces
Bioorganic & Medicinal Chemistry Letters 1998.0
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B
Bioorganic & Medicinal Chemistry Letters 2013.0
NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability
Journal of Medicinal Chemistry 2002.0
Fragment Screening and Assembly:  A Highly Efficient Approach to a Selective and Cell Active Protein Tyrosine Phosphatase 1B Inhibitor
Journal of Medicinal Chemistry 2003.0
Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical Properties
Journal of Medicinal Chemistry 2001.0